Back to search
Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
Metastatic Prostate Cancer
Clinicaltrials.gov:
Other:
#HLD-0915-ONC-101
Interested in this trial?
Subscribe or share this trial
Trials at a glance
Status
Enrolling
Condition
Metastatic Prostate Cancer
Trial type
Interventional
Trial phase
Phase 1
Investigational
product
product
JNJ-101556143 Formulation 1
JNJ-101556143 Formulation 2
JNJ-101556143 Formulation 3
Age
18+ years old
Biological sex
Male
Placebo?
No
Trial start date
February 6, 2025
Trial end date
August 17, 2028
CT.gov ID
#NCT06800313
Share the trial ID with your doctor to see if trial participation is right for you. Participation depends on an independent medical assessment.
Countries:
- United Kingdom,
- United States
Loading...
Enrolling
Syracuse, New York, United States, 13210
Enrolling
Myrtle Beach, South Carolina, United States, 29572
Enrolling
Boston, Massachusetts, United States, 02114
Enrolling
Durham, North Carolina, United States, 27710
Enrolling
Sarasota, Florida, United States, 34232
Enrolling
Houston, Texas, United States, 77030
Enrolling
Long Island City, New York, United States, 11101
Enrolling
Austin, Texas, United States, 78758
Enrolling
Colorado Springs, Colorado, United States, 80909
Enrolling
Nashville, Tennessee, United States, 37203
Enrolling
Denver, Colorado, United States, 80218
Enrolling
Grand Rapids, Michigan, United States, 49546
Enrolling
Sutton, United Kingdom, SM2 5PT
Enrolling
Nashville, Tennessee, United States, 37209
Enrolling
Omaha, Nebraska, United States, 68130
Enrolling
Norfolk, Virginia, United States, 23502
Enrolling
Metairie, Louisiana, United States, 70006
Enrolling
New Haven, Connecticut, United States, 06511
#
More than 50 sites in this region
#
More than 10 sites in this region
#
Less than 10 sites in this region
Individual sites
Access detailed information on the trial:
Clinical trials information
Key links
© Johnson & Johnson and its affiliates 2026
